Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

University of Texas MD Anderson Cancer Center

http://www.mdanderson.org/

Latest From University of Texas MD Anderson Cancer Center

OncoResponse Mines PD-1 Therapy “Elite Responders” For IO Breakthroughs

Emerging Company Profile: Harvesting blood and tissue samples from patients treated with PD-1 immunotherapy, OncoResponse is developing antibodies it believes can transform cold solid tumors into hot.

Emerging Company Profile Business Strategies

Tech Transfer Roundup: MD Anderson, Moffitt Lead Busy Academic Cancer Partnering Space

MD Anderson teams with Eisbach on precision oncology and with Yingli on a five-year translational research effort. Moffitt inks tie-ups with Dyve and Turnstone.

Tech Transfer Round-Up Deals

Amgen After ASCO: Questions Remain On Lumakras, Bemarituzumab

Remaining questions after ASCO include whether Lumakras (sotorasib) might work in first-line NSCLC with certain co-mutations and if ocular toxicities will hamper bemarituzumab in gastric cancer.

ASCO Cancer

Tech Transfer: BMS, Evotec Partner With Four UK Universities On Translational Research Efforts

The firms hope academic research can yield first-in-class therapies and spinout companies. Also, Yale unveils research alliances with three biotechs.

Tech Transfer Round-Up Deals
See All

Company Information

  • Industry
  • Academic and Research Institutions
UsernamePublicRestriction

Register